Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-7

  Hosoi, Toru ^a   Yokoyama, Shota ^a   Matsuo, Suguru ^a   Akira, Shizuo ^b   Ozawa, Koichiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; INSULIN; JANUS KINASE; LEPTIN; MYELOID DIFFERENTIATION FACTOR 88; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; LIPID DIET; LIVER DYSFUNCTION; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; RISK FACTOR;

MUS;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; OBESITY; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958536355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012537     Document Type: Article

References (33)

1. Hotamisligil GS, Erbay E (2008) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8: 923-934.
2. Lee JY, Sohn KH, Rhee SH, Hwang D (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276: 16683-16689.
3. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015-3025.
4. Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, et al. (2007) C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50: 1267-1276.
5. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56: 1986-1998.
6. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, et al. (2007) Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354: 45-49.
7. Schulthess FT, Paroni F, Sauter NS, Shu L, Ribaux P, et al. (2009) CXCL10 impairs b cell function and viability in diabetes through TLR4 signaling. Cell Metab 9: 125-139.
8. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-22.
9. Muzio M, Ni J, Feng P, Dixit VM (1997) IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278: 1612-1615.
10. Lord KA, Hoffman-Liebermann B, Liebermann DA (1990) Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants. Oncogene 5: 387-396.
11. Hultmark D (1994) Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. Biochem Biophys Res Commun 199: 144-146.
12. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, et al. (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253-258.
13. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, et al. (2004) Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279: 45803-45809.
14. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420: 333-336.
15. Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA (1994) Tumor necrosis factor a stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem 269: 26396-26401.
16. Li Y, Schwabe RF, DeVries-Seimon T, Yao PM, Gerbod-Giannone MC, et al. (2005) Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-a and interleukin-6: model of NF-kB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem 280: 21763-21772.
17. Brown MS, Kovanen PT, Goldstein JL (1981) Regulation of plasma cholesterol by lipoprotein receptors. Science 212: 628-635.
18. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
19. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
20. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
21. Lang CH, Dobrescu C, Bagby GJ (1992) Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43-52.
22. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 259: 87-91.
23. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A (1993) Tumor necrosis factor-a suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268: 26055-26058.
24. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-50.
25. Tabas I (2002) Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 110: 905-911.
26. Kleinridders A, Schenten D, Könner AC, Belgardt BF, Mauer J, et al. (2009) MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 10: 249-259.
27. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, et al. (2004) Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279: 45803-45809.
28. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKK-b links inflammation to obesity-induced insulin resistance. Nat Med. 11: 191-198.
29. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-k B. Nat Med. 11: 183-190.
30. Sandoval DA, Obici S, Seeley RJ (2009) Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov. 8: 386-398.
31. Woods SC, Lotter EC, McKay LD, Porte D, Jr (1979) Chronic intracerebro-ventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282: 503-505.
32. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, et al. (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321: 691-696.
33. Hosoi T, Sasaki M, Miyahara T, Hashimoto C, Matsuo S, et al. (2008) Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 74: 1610-1619.